Patents Assigned to CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE
  • Patent number: 11186634
    Abstract: The present invention relates to antibodies targeting Tumor Associated Macrophages (TAMs) and uses thereof. The inventors investigated specific marker exposed on the surface of the macrophages associated to tumor in order to detect and target TAMs. They showed that sideroflexin 3, which is absent in normal macrophage, is expressed by tumor associated macrophages. The inventors further demonstrated that using antibody directed to sideroflexin 3, they depleted TAMs in PBMC sample obtained from LCC patient, and strongly reduced leukemic B cells number.
    Type: Grant
    Filed: July 28, 2017
    Date of Patent: November 30, 2021
    Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Université Paul Sabatier Toulouse, Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Universitaire de Toulouse, Institut Claudius Regaud
    Inventors: Mary Poupot, Loïc Ysebaert, Marie Tosolini, Jean-Jacques Fournie, Pierre Brousset, Philippe Rochaix
  • Patent number: 11078277
    Abstract: The present invention relates to methods and pharmaceutical compositions for enhancing CD8+ T cell-dependent immune responses in subjects suffering from cancer. In particular, the present invention relates to a method of enhancing the CD8+ T cell-dependent immune response in a subject suffering from cancer comprising administering to the subject a therapeutically effective amount of an agent capable of increasing intra-tumoral ceramide content.
    Type: Grant
    Filed: February 1, 2017
    Date of Patent: August 3, 2021
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PAUL SABATIER TOULOUSE III, CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE
    Inventors: Thierry Levade, Bruno Segui, Florie Bertrand, Julia Rochotte, Anne Montfort, Nathalie Andrieu-Abadie, Celine Colacios Viatge, Nicolas Meyer
  • Patent number: 11061037
    Abstract: Disclosed herein is a method for classifying a patient at risk for heart failure, wherein the method comprises the steps of (i) measuring the concentration of IGFBP2 in a sample obtained from the patient and (ii) comparing the concentration of IGFBP2 measured in step (i) to a control value derived from the concentration of IGFBP2 in samples from patients who are at particular stages of heart failure and/or to a control value derived from the concentration of IGFBP2 in blood samples from healthy patients.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: July 13, 2021
    Assignees: INSERM (INSTITUT DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PAUL SABATIER TOULOUSE III, CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE
    Inventors: Philippe Rouet, Fatima Smih-Rouet, Franck Desmoulin, Michel Galinier
  • Patent number: 10918737
    Abstract: The present invention relates to methods and pharmaceutical composition for the treatment of cancer. In particular, the present invention relates to a method for enhancing the potency of an immune checkpoint inhibitor administered to a subject as part of a treatment regimen for cancer, the method comprising: administering a pharmaceutically effective amount of a TNF? blocking agent to a subject in combination with the immune checkpoint inhibitor.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: February 16, 2021
    Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Université Paul Sabatier Toulouse III, Centre Hospitalier Universitaire de Toulouse
    Inventors: Thierry Levade, Bruno Segui, Nicolas Meyer, Céline Colacios Viatgé, Nathalie Andrieu-Abadie, Florie Bertrand
  • Patent number: 10822415
    Abstract: The present invention relates to methods for enhancing the potency of the immune checkpoint inhibitors. In particular, the present invention relates to a method for enhancing the potency of an immune checkpoint inhibitor administered to a subject as part of a treatment regimen, the method comprising administering a pharmaceutically effective amount of a SK1 inhibitor to a subject in combination with the immune checkpoint inhibitor.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: November 3, 2020
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉET DE LA RECHERCHE MÉDICALE), Université Toulouse III—Paul Sabatier, CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE
    Inventors: Thierry Levade, Nicolas Meyer, Céline Colacios Viatgé, Caroline Imbert, Nathalie Andrieu-Abadie, Bruno Segui
  • Patent number: 10781293
    Abstract: The present invention relates to a process for preparing a biocompatible and biodegradable, porous three-dimensional polymer matrix, to the porous polymer matrix obtained by means of such a process, and also to the uses thereof, in particular as a support and for cell culture or in regenerative medicine, and in particular for cell therapy, in particular cardiac cell therapy.
    Type: Grant
    Filed: July 27, 2016
    Date of Patent: September 22, 2020
    Assignees: CENTRE HOSPITALIER UNIVERSITAIRE DE Toulouse, CENTRE NATIONAL DE LA RECHERCHE Scientifique
    Inventors: Sophie Girod Fullana, Brigitte Sallerin, Raya Bushkalova, Caroline Ceccaldi
  • Patent number: 10760135
    Abstract: The present invention relates to methods for predicting pancreatic cancer treatment response.
    Type: Grant
    Filed: January 13, 2016
    Date of Patent: September 1, 2020
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PAUL SABATIER TOULOUSE III, CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE
    Inventors: Pierre Cordelier, Louis Buscail, Frédéric Lopez
  • Patent number: 10709776
    Abstract: The present invention relates to ex vivo method for producing outer membrane vesicles (OMVs) by expression or overexpression of the hemolysin F gene (hlyF) in gram-negative bacterium.
    Type: Grant
    Filed: April 7, 2015
    Date of Patent: July 14, 2020
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT, UNIVERSITÉ PAUL SABATIER TOULOUSE III, CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE
    Inventors: Eric Oswald, Patricia Martin, Kazunori Murase
  • Patent number: 10705076
    Abstract: A method for determining the quantity of anti-HLA antibodies of a liquid medium containing antibodies.
    Type: Grant
    Filed: February 15, 2013
    Date of Patent: July 7, 2020
    Assignees: UNIVERSITÉ PAUL SABATIER TOULOUSE III, CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE
    Inventors: Antoine Blancher, Nicolas Congy, Jean-Gerard Tiraby, Daniel Drocourt
  • Publication number: 20200081009
    Abstract: The invention concerns an inhibitor of the expression of chemokine CCL7 or an inhibitor of the expression of the receptor CCR3 or an inhibitor of CCL7/CCR3 interaction for the use of same to prevent or treat the extension of prostate cancer outside the prostatic capsule in a subject. The invention also concerns a method for determining the degree of aggressiveness of a prostate cancer tumour in a subject suffering from prostate cancer, comprising a step of determining the concentration or level of expression of the receptor CCR3 in a sample of prostate tumour cells obtained from said subject.
    Type: Application
    Filed: July 15, 2019
    Publication date: March 12, 2020
    Applicants: Universite Paul Sabatier (Toulouse III), Centre National de la Recherche Scientifique, Centre Hospitalier Universitaire de Toulouse, Institute National de la Sante et de la Recherche Medicale (INSRM)
    Inventors: Catherine Muller, Victor Laurent, Adrien Guerard, Philippe Valet, Bernard Malavaud
  • Patent number: 10426818
    Abstract: The present invention relates to an APJ receptor agonist for use in the treatment or the prevention of diabetes.
    Type: Grant
    Filed: March 23, 2016
    Date of Patent: October 1, 2019
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Universite Paul Sabatier Toulouse, Centre Hospitalier Universitaire de Toulouse
    Inventors: Philippe Valet, Isabelle Laurell, Laurent Cazals, Pierre Gourdy
  • Patent number: 10401365
    Abstract: The invention concerns an inhibitor of the expression of chemokine CCL7 or an inhibitor of the expression of the receptor CCR3 or an inhibitor of CCL7/CCR3 interaction for the use of same to prevent or treat the extension of prostate cancer outside the prostatic capsule in a subject. The invention also concerns a method for determining the degree of aggressiveness of a prostate cancer tumor in a subject suffering from prostate cancer, comprising a step of determining the concentration or level of expression of the receptor CCR3 in a sample of prostate tumor cells obtained from said subject.
    Type: Grant
    Filed: June 16, 2015
    Date of Patent: September 3, 2019
    Assignees: Universite Paul Sabatier (Toulouse III), Centre National de la Recherche Scientifique, Centre Hospitalier Universitaire de Toulouse, Institut National de la Sante et de la Recherche Medicale
    Inventors: Catherine Muller, Victor Laurent, Adrien Guerard, Philippe Valet, Bernard Malavaud
  • Publication number: 20190031757
    Abstract: The present invention relates to methods for enhancing the potency of the immune checkpoint inhibitors. In particular, the present invention relates to a method for enhancing the potency of an immune checkpoint inhibitor administered to a subject as part of a treatment regimen, the method comprising administering a pharmaceutically effective amount of a SK1 inhibitor to a subject in combination with the immune checkpoint inhibitor.
    Type: Application
    Filed: January 27, 2017
    Publication date: January 31, 2019
    Applicants: INSERM (Institut National De La Santé et de La Recherche Médicale, Université Paul Sabatier Toulouse III, Centre Hospitalier Universitaire de Toulouse
    Inventors: Thierry LEVADE, Nicolas MEYER, Céline COLACIOS VIATGÉ, Caroline IMBERT, Nathalie ANDRIEU-ABADIE, Bruno SEGUI
  • Patent number: 10188666
    Abstract: Dendrogenin A and antineoplastic agents for the treatment of chemosensitive or chemoresistant tumors. The invention concerns a kit-of-parts comprising 5?-hydroxy-6?-[2-(1H-imidazol-4-yl)ethylamino]cholestan-3?-ol (Dendrogenin A) or a pharmaceutically acceptable salt thereof and an antineoplastic agent for use in the treatment of cancer. Furthermore, the invention concerns Dendrogenin A or a pharmaceutically acceptable salt thereof for use for treating a chemoresistant cancer.
    Type: Grant
    Filed: September 3, 2014
    Date of Patent: January 29, 2019
    Assignees: AFFICHEM, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE
    Inventors: Philippe de Medina, Michael Paillasse, Christian Recher, Marc Poirot, Sandrine Silvente Poirot
  • Patent number: 10144772
    Abstract: The present invention relates to a TNF? blocking agent for use in the treatment and prevention of melanoma in a subject in whom melanoma cells express MHCI and in whom stroma cells exhibit TNF expression.
    Type: Grant
    Filed: May 12, 2015
    Date of Patent: December 4, 2018
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Centre Hospitalier Universitaire de Toulouse, Institut Claudius Regaud, Universite Paul Sabatier Toulouse III
    Inventors: Bruno Segui, Nathalie Andrieu-Abadie, Thierry Levade, Celine Colacios Viatge, Philippe Rochaix, Florie Bertrand, Herve Benoist, Julia Rochotte
  • Patent number: 9945871
    Abstract: The present invention relates to a method for assessing a subject's risk of having a cardiovascular disease comprising the step of measuring the level of IF1 in a body fluid sample obtained from said subject wherein the level of EF1 is negatively correlated with the risk of said subject of having cardiovascular disease.
    Type: Grant
    Filed: April 23, 2015
    Date of Patent: April 17, 2018
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE
    Inventors: Laurent Martinez, Bertrand Perret, Annelise Genoux
  • Publication number: 20180049726
    Abstract: The invention relates to a device for capture of cellular biomarkers circulating in an animal or human biological flow, characterised in that it is suitable for use in vivo and in that it comprises a means of filtration intended to retain the said cellular biomarkers, the said means of filtration comprising at least one through-aperture the dimensions of which are suitable for retaining the said cellular biomarkers and being integral with a support, the support taking the form of a hollow component.
    Type: Application
    Filed: February 2, 2016
    Publication date: February 22, 2018
    Applicants: Centre National de la Recherche Scientifique, Centre Hospitalier Universitaire de Toulouse, Universite Toulouse III - Paul Sabatier
    Inventors: Aline Cerf, Sylvain Sanson, Hélène Cayron, Alejandro Kayum Jimenez, Christophe Vieu, Bernard Malavaud
  • Patent number: 9851358
    Abstract: The present invention relates to methods and pharmaceutical compositions for preventing or reducing metastatic dissemination (i.e. reducing motility of cancer cells). In particular, the present invention relates to a method for preventing or reducing metastatic dissemination (i.e. reducing motility of cancer cells) in a subject suffering from a cancer comprising the steps consisting of i) determining the expression level of at least one biomarker selected from the group consisting of soluble CD95L and EMT promoting factors in a sample obtained from the subject, ii) comparing the expression level determined at step i) with a predetermined reference value and iii) administering the subject with a therapeutically effective amount of C16-ceramide or derivatives such as C16-sphingomyelin and C16-glycosphingolipids when the expression level determined at step i) is higher than the predetermined reference value.
    Type: Grant
    Filed: January 7, 2015
    Date of Patent: December 26, 2017
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Universite Paul Sabatier Toulouse III, Centre Hospitalier Universitaire de Toulouse, Universite de Bourgogne, Universite de Rennes I, Universit des Antilles et de la Guiyane, Ecole des Hautes Etudes en Sante Publique (EHESP)
    Inventors: Patrick Legembre, Bruno Segui, Thierry Levade, Olivier Micheau
  • Publication number: 20170248582
    Abstract: The present invention concerns the development of a model to evaluate active substances targeting the epidermis. It more particularly relates to the preparation of mixed spheroids of melanocytes and keratinocytes reproducing cell interactions occurring in the epidermis, to the spheroids as such and to the uses thereof.
    Type: Application
    Filed: October 29, 2015
    Publication date: August 31, 2017
    Applicants: Syntivia, Centre Hospitalier Universitaire de Toulouse, Universite Paul Sabatier - Toulouse III, Centre National de la Recherche Scientifique
    Inventors: Marine Norlund, Bernard Ducommun, Philippe Bedos, Valérie Lobjois
  • Patent number: 9637538
    Abstract: A monoclonal chimeric immunoglobulin wherein the heavy chains and the light chains are human by nature in their constant parts, in particular, the heavy chain constant parts are chosen from the group formed of the heavy chain constant parts of an IgA, of an IgG or of an IgM and the light chain constant parts are chosen from the group formed of the kappa chains and the lambda chains, and the light chain and the heavy chain variable parts are chosen from the group formed of monoclonal antibodies specific to monomorphic epitopes of HLA class I antigens and monoclonal antibodies specific to monomorphic epitopes of HLA class II antigens. A process for standardization of the screening and for quantification of anti-HLA antibodies in a liquid medium is also described.
    Type: Grant
    Filed: April 24, 2013
    Date of Patent: May 2, 2017
    Assignees: UNIVERSITE PAUL SABATIER TOULOUSE III, CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE, INVIVOGEN
    Inventors: Antoine Blancher, Nicolas Congy, Jean-Gerard Tiraby, Daniel Drocourt